Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction

International Journal of STD and AIDS

Volumn 14, Issue 7, 2003, Pages 478-481

  Keiser, Philip ^a,c   Nassar, Naiel ^a   Skiest, Daniel ^a   Andrews, Charla ^a   Yazdani, Beena ^a   White, Alice ^b   Hetherington, Seth ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NONE   (United States)

Author keywords

Allergy; Antiretroviral therapy; Hypersensitivity; Influenza

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE;

ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; SORE THROAT; VOMITING;

ANTI-HIV AGENTS; CASE-CONTROL STUDIES; COUGH; DIAGNOSIS, DIFFERENTIAL; DIDEOXYNUCLEOSIDES; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0038682515     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646203322025795     Document Type: Article

References (10)

1. Saag MS, Sonnerberg A, Torres RA, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team. AIDS 1998;12:203-9
2. Staszewski S, Katlama C, Herres T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS 1998;12:197-202
3. Hervey PS, Perry CM. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 2000;60:447-79
4. Saez-Llorens X, Nelson RL Jr, Emmanuel P, et al. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team. Pediatrics 2001;107:4
5. Hetherington SS, Naderer H, Cutrell O, Powell A, Sykes R, McGuirk S. Hypersensitivity reactions during therapy with abacavir: clinical presentation and risk factors. In 7th Conference on Retroviruses and Opportunistic Infections. 2000
6. Staszewski S, Keiser P, Montaner J, et al. A randomized double blind equivalence trial comparing triple nucleoside therapy of abacavir, lamivudine, and zidovudine with indinavir, lamivudine and zidovudine in anti-retroviral naïve HIV-1 infected adults. JAMA 2001;285:1155-63
7. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999;13:999-1000
8. Frissen PH, de Vries J, Weigel HM, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS 2001;15:289
9. Mallal S, Nolan D, Witt C, et al. The presence of HLA-B*5701, -DRB1*0701, and DQ3 is highly predictive of hypersensitivity to the HIV reverse transcriptase inhibitor abacavir. 9th Conference on Retroviruses and Opportunistic Infections. Chicago 2002
10. Hetherington S, Hughes AR, Mosteller M, et al. HLA-B57 and TNF-alpha variants associated with hypersensitivity reactions to abacavir among HIV-1 positive subjects. 9th Conference on Retroviruses and Opportunistic Infections. Chicago 2002